Search results for "Immune defence"

showing 10 items of 19 documents

Variation and covariation in infectivity, virulence and immunodepression in the host-parasite association Gammarus pulex-Pomphorhynchus laevis.

2009

Parasites often manipulate host immunity for their own benefit, either by exacerbating or suppressing the immune response and this may directly affect the expression of parasite virulence. However, genetic variation in immunodepression, which is a prerequisite to its evolution, and the relationship between immunodepression and virulence, have rarely been studied. Here, we investigated the variation among sibships of the acanthocephalan parasite, Pomphorhynchus laevis , in infecting and in immunodepressing its amphipod host, Gammarus pulex . We also assessed the covariation between infectivity, parasite-induced immune depression and host mortality (parasite virulence). We found that infecti…

0106 biological sciencesVirulencephenoloxidaseparasite-induced immunodepression[ SDV.IMM.IA ] Life Sciences [q-bio]/Immunology/Adaptive immunology010603 evolutionary biology01 natural sciencesGeneral Biochemistry Genetics and Molecular BiologyMicrobiologyAcanthocephalaHost-Parasite Interactions03 medical and health sciencesImmune systemRiversImmunityResearch articlesImmune Tolerance[ SDV.EE.IEO ] Life Sciences [q-bio]/Ecology environment/SymbiosisParasite hostingAnimalsAmphipoda030304 developmental biologyGeneral Environmental ScienceInfectivity0303 health sciences[ SDE.BE ] Environmental Sciences/Biodiversity and EcologyGeneral Immunology and MicrobiologybiologycovariationHost (biology)Monophenol MonooxygenaseGeneral Medicinebiology.organism_classificationSurvival Analysis3. Good healthacanthocephalanvirulenceGammarus pulex[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunologyImmunologyimmune defencesPomphorhynchus laevisFrance[SDE.BE]Environmental Sciences/Biodiversity and EcologyGeneral Agricultural and Biological Sciences[SDV.EE.IEO]Life Sciences [q-bio]/Ecology environment/Symbiosis
researchProduct

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion

2018

The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46%…

MaleBLOODDatabases FactualIMPACTCHROMOSOMECancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]medicine.medical_treatment[SDV]Life Sciences [q-bio]MedizinHematopoietic stem cell transplantationPROGNOSTIC SCORING SYSTEMGastroenterology0302 clinical medicineRecurrencehemic and lymphatic diseasesMDSCumulative incidenceLENALIDOMIDEIncidenceIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationHematologyMiddle AgedAllograftsTP53 MUTATIONSEUROPEAN-SOCIETY3. Good healthSurvival Rate030220 oncology & carcinogenesisWORKING PARTYChromosomes Human Pair 5FemaleChromosome DeletionLife Sciences & BiomedicineDEL(5Q)del (5q)medicine.drugAdultmedicine.medical_specialtyImmunology3122 CancersDisease-Free SurvivalSettore MED/01 - Statistica Medica03 medical and health sciencesSex FactorsAll institutes and research themes of the Radboud University Medical CenterInternal medicinemedicineHumansMARROW-TRANSPLANTATIONSurvival rateLenalidomideTransplantationScience & Technologybusiness.industryMyelodysplastic syndromesmedicine.diseaseAllogeneic stem cell transplantationTransplantationMyelodysplastic Syndromesbusiness030215 immunology
researchProduct

Robust Antigen-Specific T Cell Activation within Injectable 3D Synthetic Nanovaccine Depots

2021

Contains fulltext : 244693.pdf (Publisher’s version ) (Open Access) Synthetic cancer vaccines may boost anticancer immune responses by co-delivering tumor antigens and adjuvants to dendritic cells (DCs). The accessibility of cancer vaccines to DCs and thereby the delivery efficiency of antigenic material greatly depends on the vaccine platform that is used. Three-dimensional scaffolds have been developed to deliver antigens and adjuvants locally in an immunostimulatory environment to DCs to enable sustained availability. However, current systems have little control over the release profiles of the cargo that is incorporated and are often characterized by an initial high-burst release. Here,…

Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]T-LymphocytesT cellBiomedical Engineering02 engineering and technologySDG 3 – Goede gezondheid en welzijnantigen-specific T cellsCancer VaccinesArticleBiomaterials03 medical and health sciencesbiomaterial-based scaffoldsImmune systemAntigenSDG 3 - Good Health and Well-beingAntigen specificControlled deliverymedicineLactic Aciddendritic cells030304 developmental biology0303 health sciencesChemistryBiomaterial021001 nanoscience & nanotechnologyCell biologymedicine.anatomical_structureDelivery efficiencynanoparticles0210 nano-technologycancer vaccinationNanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19]Polyglycolic Acid
researchProduct

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer

2015

Abstract Tumor growth in the context of EGFR inhibitor resistance may remain EGFR-dependent and is mediated by mechanisms including compensatory ligand upregulation and de novo gene alterations. Sym004 is a two-antibody mixture targeting nonoverlapping EGFR epitopes. In preclinical models, Sym004 causes significant EGFR internalization and degradation, which translates into superior growth inhibition in the presence of ligands. In this phase I trial, we observed grade 3 skin toxicity and hypomagnesemia as mechanism-based dose-limiting events during dose escalation. In dose-expansion cohorts of 9 and 12 mg/kg of Sym004 weekly, patients with metastatic colorectal cancer and acquired EGFR inhi…

AdultMaleProto-Oncogene Proteins B-rafClass I Phosphatidylinositol 3-KinasesColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Antineoplastic AgentsContext (language use)Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]LigandsPhosphatidylinositol 3-Kinaseschemistry.chemical_compoundCell Line TumorHumansMedicinePanitumumabNeoplasm MetastasisAgedEGFR inhibitorsAged 80 and overDose-Response Relationship DrugCetuximabbusiness.industryGene AmplificationAntibodies MonoclonalCancerMiddle Agedmedicine.diseaseErbB ReceptorsClinical trialGenes rasTreatment OutcomeOncologychemistryMutationImmunologyCancer researchFemaleGrowth inhibitionColorectal Neoplasmsbusinessmedicine.drug
researchProduct

PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses

2021

Contains fulltext : 232076.pdf (Publisher’s version ) (Open Access) Tumor-specific neoantigens can be highly immunogenic, but their identification for each patient and the production of personalized cancer vaccines can be time-consuming and prohibitively expensive. In contrast, tumor-associated antigens are widely expressed and suitable as an off the shelf immunotherapy. Here, we developed a PLGA-based nanoparticle vaccine that contains both the immunogenic cancer germline antigen NY-ESO-1 and an α-GalCer analog IMM60, as a novel iNKT cell agonist and dendritic cell transactivator. Three peptide sequences (85-111, 117-143, and 157-165) derived from immunodominant regions of NY-ESO-1 were se…

CD4-Positive T-Lymphocyteslcsh:Immunologic diseases. AllergyCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]T cellmedicine.medical_treatment[SDV]Life Sciences [q-bio]ImmunologyCD8-Positive T-Lymphocyteschemistry.chemical_compoundPolylactic Acid-Polyglycolic Acid CopolymerAntigenmedicinepeptide vaccineHumansImmunology and AllergyCytotoxic T cellNY-ESO-1B cellOriginal ResearchB-LymphocytesDrug CarriersDendritic cellImmunotherapyCD4 T cellPLGA nanoparticleIMM60Peptide FragmentsNeoplasm Proteins[SDV] Life Sciences [q-bio]PLGAmedicine.anatomical_structurechemistryCD8 T cellCancer researchB cell epitopeiNKT cellNanoparticleslcsh:RC581-607CD8
researchProduct

Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leuke…

2014

Item does not contain fulltext In chronic lymphocytic leukemia (CLL) medical progress is driven by clinical studies with relapse-free survival (RFS) as the primary endpoint. The randomized EBMT-Intergroup trial compared high-dose therapy and autologous stem cell transplantation (ASCT) to observation and demonstrated a substantial improvement of RFS without showing improved overall survival for the transplant arm. Here we report quality of life (QoL) information of the first 3 years following randomization from that study. The main objective was to assess the impact of treatment on QoL over time. Two secondary analyses were performed to further investigate the impact of ASCT and relapse on Q…

AdultMaleOncologymedicine.medical_specialtyTransplantation ConditioningRandomizationCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2][SDV]Life Sciences [q-bio]medicine.medical_treatmentChronic lymphocytic leukemiaHematopoietic stem cell transplantationTransplantation Autologous03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationQuality of lifeRecurrenceSurveys and QuestionnairesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansComputingMilieux_MISCELLANEOUSAgedbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-Cellhumanities3. Good healthSurgeryTransplantation030220 oncology & carcinogenesisQuality of LifeFemaleTransplantation Conditioningbusiness030215 immunologyAmerican Journal of Hematology
researchProduct

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

2016

Contains fulltext : 165965.pdf (Publisher’s version ) (Closed access) Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and speciali…

0301 basic medicineOncologymedicine.medical_specialtyEvidence-based practiceBevacizumabColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Guidelines as Topiccolorectal cancerRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]03 medical and health scienceschemistry.chemical_compoundClinical practice guidelines; Colorectal cancer; Consensus; ESMO; Hematology; Oncology0302 clinical medicineGuia de Práctica ClínicaInternal medicineBiomarkers TumormedicineHumansMolecular Targeted TherapyNeoplasm MetastasisIntensive care medicineTipiracilNeoplasias Colorrectais/tratamentoFOLFOXIRIbusiness.industryESMO; clinical practice guidelines; colorectal cancer; consensusCancerHematologyESMOPrognosismedicine.diseaseDebulkingChemotherapy regimendigestive system diseases3. Good health030104 developmental biologyPractice GuidelineOncologychemistryColorectal Neoplasms/therapyconsensus030220 oncology & carcinogenesisColorectal Neoplasmsbusinessclinical practice guidelinesclinical practice guidelinemedicine.drug
researchProduct

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective …

2017

Abstract Introduction:Even in the era of novel targeted therapies for the treatment of Chronic Lymphocytic Leukemia (CLL) patients, such as BTK, PI3K and BCL2 inhibitors, allogeneic hematopoietic stem cell transplantations (alloHCT) will remain an important treatment option for a subset of patients with very high risk CLL. The current study focused on the impact of center and procedure-related factors on outcomes after alloHCT, taking into account the impact of patient- and disease-related risk factors. Patients and Methods:Data of 684 CLL patients who received a first alloHCT between 2000 and 2011 were analyzed. Their data were collected as part of the EBMT CLL Data Quality Initiative. Out…

OncologyMaleTransplantation ConditioningCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Chronic lymphocytic leukemiaMedizinQUALITY MANAGEMENT-SYSTEMKaplan-Meier Estimaterisk factor analysisGUIDELINESBiochemistryallogeneic stem cell transplantation; centre effects; chronic lymphocytic leukaemia; frailties; risk factor analysiscentre effectsTransplantation Conditioning / methods0302 clinical medicineRecurrenceRisk Factorsallogeneic stem cell transplantationLeukemia Lymphocytic Chronic B-Cell / mortalityRegistriesDelivery of Health Care / statistics & numerical dataIBRUTINIBddc:6160303 health sciencesALEMTUZUMABHazard ratioHematopoietic Stem Cell TransplantationProfessional PracticeHematologyMiddle Aged3. Good healthEurope030220 oncology & carcinogenesisABT-199CohortSURVIVALAlemtuzumabFemaleEurope / epidemiologymedicine.drugAdultmedicine.medical_specialtyAllogeneic transplantationImmunologyLower riskDIAGNOSISSettore MED/01 - Statistica Medica03 medical and health sciencesLeukemia Lymphocytic Chronic B-Cell / therapyHematopoietic Stem Cell Transplantation / methodsInternal medicinemedicineHumansKarnofsky Performance Status030304 developmental biologyAgedRetrospective Studiesbusiness.industryProportional hazards modelCHRONIC LYMPHOCYTIC-LEUKEMIARetrospective cohort studySTEM-CELL TRANSPLANTATIONCell Biologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellConfidence intervalSurgeryProfessional Practice / statistics & numerical dataTransplantationbusinessDelivery of Health Carefrailtieschronic lymphocytic leukaemia030215 immunologyRESPONSES
researchProduct

Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance.

2018

Cell-based assays to monitor antigen-specific T-cell responses are characterized by their high complexity and should be conducted under controlled conditions to lower multiple possible sources of assay variation. However, the lack of standard reagents makes it difficult to directly compare results generated in one lab over time and across institutions. Therefore TCR-engineered reference samples (TERS) that contain a defined number of antigen-specific T cells and continuously deliver stable results are urgently needed. We successfully established a simple and robust TERS technology that constitutes a useful tool to overcome this issue for commonly used T-cell immuno-assays. To enable users t…

0301 basic medicineRNA StabilityComputer scienceT cellPerformanceCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]RNA StabilityT-LymphocytesImmunologyCell Culture TechniquesComputational biology03 medical and health sciences0302 clinical medicineAll institutes and research themes of the Radboud University Medical CenterHigh complexityValidationHLA-A2 AntigenmedicineImmunology and AllergyHumansImrnunoguidingRNA MessengerCell EngineeringT-cell assaysReceptors Chimeric AntigenImmunomagnetic SeparationElectroporationT-cell receptorRNAReference StandardsStandardizationImmunomonitoring030104 developmental biologymedicine.anatomical_structureElectroporationBlood Buffy CoatFeasibility StudiesBiological Assay030215 immunologyJournal of immunological methods
researchProduct

Complement genetics: biological implications of polymorphisms and deficiencies

1999

Abstract Complement (C) proteins form a highly complex and important humoral host immune defence system. A recent meeting**The VII Complement Genetics Workshop and Conference was held at Mainz, Germany, on 21–23 May 1998. addressed the role of genetic studies of C components and its regulators with respect to evolution, function and human disease.

Immune defenceGeneticsHuman diseaseImmunologyBiologyFunction (biology)Complement (complexity)Immunology Today
researchProduct